By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BG Medicine said Wednesday that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of BG's common stock for $7 per share.

In total, BG sold 5.75 million shares at a price of $7 per share in the offering. The firm said in its prospectus for the offering that if the underwriters' over-allotment option was exercised in full, its net proceeds would be approximately $35.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.